Key result
Combined isoflavone compound cuts vasomotor symptoms by ~83 percentage points from baseline at 12 months.
Answers are grounded in this paper and cite their sources.
Clinical trial shows reduced climacteric symptoms and improved cardiometabolic markers in postmenopausal women, indicating long-term multi-system benefits.
Objective To evaluate the long-term effects of a combination of isoflavones, agnus castus and magnolia extracts (combined isoflavone compound [CIC]) on climacteric symptoms and cardiometabolic risk in symptomatic postmenopausal women.Methods This interventional, prospective study evaluated climacteric symptoms, mood and sleep disorders using the 21-item Greene Climacteric Scale (GCS) and 7-item Insomnia Severity Index (ISI) questionnaires; and cardiovascular, metabolic and thrombotic risk markers at baseline (T0) and after 12 months of CIC treatment (T1).Results In healthy postmenopausal women (N = 71), 12-month CIC treatment significantly reduced patient-reported vasomotor symptoms (100% vs. 17%), mood disorders (67% vs. 25%) and sleep disorders (89% vs. 19%%) (all p < .001) compared with baseline; and significantly improved GCS psychological, somatic, and vasomotor domain scores and ISI sleep disturbance scores (all p < .05). CIC significantly reduced systolic (p = .022) and diastolic blood pressure (p < .001), and heart rate (p < .001); glucose concentrations (p = .018), HOMA index (p = .013), and ALT (p = .035), homocysteine (p = .005) and NT-proBNP (p = .003) levels.Conclusions Long-term CIC therapy improved vasomotor symptoms, mood disorders, sleep disorders, hemodynamic measurements and cardiometabolic risk markers in healthy postmenopausal women. ClinicalTrials.gov Identifier NCT03699150.
No takes yet. Share an insight, caveat, or question.
Maffei et al. (2022) studied Climacteric symptoms and cardiometabolic risk in postmenopausal women (n=71). Combined isoflavone compound (isoflavones, agnus castus, and magnolia extracts) vs. Baseline (pre-treatment) was evaluated on Patient-reported vasomotor symptoms (p=<0.001). Combined isoflavone compound for 12 months reduced vasomotor symptoms, mood disorders, and sleep disorders vs baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: